首页> 外文期刊>Journal of Medical Virology >Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly.
【24h】

Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly.

机译:1997/1998流感疫苗与主要的流行性A(H3N2)病毒株之间的不匹配,是老年人中疫苗诱导的对该株免疫应答不足的原因。

获取原文
获取原文并翻译 | 示例
           

摘要

The success of influenza vaccination depends largely on the antigenic match between the influenza vaccine strains and the virus strains actually circulating during the season. In the past, this match has proved to be satisfactory in most seasons. In the 1997/1998 season, however, hemagglutination inhibition (HI) assays with ferret antisera indicated a considerable mismatch between the H3N2 vaccine component and the most prevalent epidemic influenza A(H3N2) virus. The results from antigenic analyses using pre- and postvaccination serum samples from volunteers of various ages, including residents of nursing homes who were more than 60 years of age, were in good agreement with the results obtained with ferret antisera. Homologous serum antibody responses to the H3N2 vaccine component as well as the cross-reactivity of the induced antibodies to the epidemic H3N2 strain, declined with increasing age of the vaccinees. As a consequence of these two effects, 84% of the vaccinees over 75 years of age did not develop HI antibody titers >/= 40 against the major H3N2 virus variant of 1997/1998, suggesting that they were not protected against infection with this virus variant. These findings support the current policy of the World Health Organization (WHO), which is to base worldwide influenza virus surveillance on results predominantly obtained by antigenic analyses of influenza virus isolates with ferret antisera in HI tests. If an antigenic mismatch is observed, the protective efficacy of the vaccine, especially for the elderly, may be insufficient. The observations also support the current policy to include the elderly in serologic efficacy trials. Copyright 2000 Wiley-Liss, Inc.
机译:流感疫苗接种的成功很大程度上取决于流感疫苗株与本季节实际传播的病毒株之间的抗原匹配。过去,这种比赛在大多数季节都令人满意。然而,在1997/1998季节,用雪貂抗血清进行的血凝抑制(HI)分析表明,H3N2疫苗成分与最流行的A型流行性流感病毒(H3N2)之间存在相当大的不匹配。使用来自不同年龄志愿者(包括60岁以上的疗养院居民)的疫苗接种前后的血清样本进行的抗原分析结果与雪貂抗血清的结果非常吻合。随着疫苗接种者年龄的增长,对H3N2疫苗成分的同源血清抗体反应以及诱导的抗体对流行性H3N2菌株的交叉反应性下降。由于这两种作用,超过75岁的84%的疫苗未针对1997/1998年主要H3N2病毒变异株产生HI抗体效价> / = 40,表明它们没有受到这种病毒感染的保护变体。这些发现支持了世界卫生组织(WHO)的当前政策,该政策将全球流感病毒监测以主要通过在HI测试中用雪貂抗血清对流感病毒分离株进行抗原分析获得的结果为基础。如果发现抗原不匹配,则疫苗的保护功效可能不足,尤其是对老年人而言。这些观察结果也支持当前的政策,将老年人纳入血清学功效试验中。版权所有2000 Wiley-Liss,Inc.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号